Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists

Australasian Journal of Dermatology

Volumn 53, Issue 4, 2012, Pages

  Lamrock, Edwina ^a   Brown, Pam ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

cutaneous sarcoidosis; granulomatous disease; sarcoidosis; tumour necrosis factor alpha antagonist

Indexed keywords

ETANERCEPT; ETHAMBUTOL; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; PIROXICAM; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; SALAZOSULFAPYRIDINE;

ADULT; ARTHRITIS; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MEDICAL HISTORY; PSORIASIS; PSORIATIC ARTHRITIS; SARCOIDOSIS; SKIN BIOPSY; SPONDYLOARTHROPATHY; TUBERCULOSIS;

ARTHRITIS, PSORIATIC; DRUG ERUPTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SARCOIDOSIS; SKIN DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869496663     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2011.00863.x     Document Type: Article

References (15)

1. Wolverton S,. Comprehensive Dermatologic Drug Therapy, 2nd edn. Philadelphia, PA: Elsevier, 2007; 361.
2. Lecluse LL, Dowlatshahi EA, Limpens CE, et al,. Etanercept: an overview of dermatologic adverse events. Arch. Dermatol. 2011; 147: 79-94.
3. Sweiss NJ, Welsch MJ, Curran JJ, et al,. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum. 2005; 53: 788-91. (Pubitemid 41463847)
4. Toussirot E, Pertuiset E, Kantelip B, et al,. Sarcoidosis occurring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin. Exp. Rheumatol. 2008; 26: 471-5. (Pubitemid 352003220)
5. Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC, et al,. Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 2006; 55: 817-20. (Pubitemid 44619198)
6. Almodovar R, Izquierdo M, Zarco P, et al,. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin. Exp. Rheumatol. 2007; 25: 99-101. (Pubitemid 46477494)
7. O'Shea FD, Marras TK, Inman RD,. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum. 2006; 55: 978-81. (Pubitemid 44917474)
8. Sturfelt G, Christensson B, Bynke G, et al,. Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J. Rheumatol. 2007; 34: 2313-14. (Pubitemid 350076897)
9. Massara A, Cavazzini L, La Corte R, et al,. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new 'class effect' paradoxical phenomenon. Two case reports and literature review. Semin. Arthritis Rheum. 2010; 39: 313-19.
10. Daien CI, Monnier A, Claudepierre P, et al,. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009; 48: 883-6.
11. Cuchacovich R, Hagan J, Khan T, et al,. Tumor necrosis factor-alpha (TNF-alpha)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature. Clin. Rheumatol. 2011; 30: 133-7.
12. Vavricka SR, Wettstein T, Speich R, et al,. Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy. Thorax 2003; 58: 278-9. (Pubitemid 36308009)
13. Peno-Green L, Lluberas G, Kingsley T, et al,. Lung injury linked to etanercept therapy. Chest 2002; 122: 1858-60. (Pubitemid 35366106)
14. Dubosc AE, Perroud AM, Bagot M, et al,. Cutaneous granulomas during infliximab therapy for spondyloarthropathy. J. Rheumatol. 2008; 35: 1222-3.
15. Takahashi H, Kaneta K, Honma M, et al,. Sarcoidosis during infliximab therapy for Crohn's disease. J. Dermatol. 2010; 37: 471-4.